Life Sciences Investment Surges as Lab Vacancy Hits Record

Life sciences investment surged even as laboratory vacancy set a record, according to a new report from GlobeSt, a commercial real estate news outlet. The pairing defines the sector's current moment: money is moving back into the asset class while the physical footprint of the industry keeps outstripping demand.

The two trends run in opposite directions, and that tension is the story. On one side, investors are deploying fresh capital into life sciences assets after a prolonged pullback. On the other, the amount of empty laboratory space has reached a level the market has never recorded before.

Lab vacancy has been climbing since the pandemic-era boom cooled. Developers delivered a wave of new wet-lab and research buildings into markets such as Boston, San Diego and the San Francisco Bay Area just as biotech tenants, squeezed by higher interest rates and a slower funding environment for drug developers, stopped expanding. The result is a record share of vacant lab space across major U.S. life sciences markets, per the GlobeSt report.

At the same time, the investment side of the ledger is improving. The GlobeSt report describes a surge in life sciences investment — a signal that institutional capital, from private equity to real estate funds, sees value in a sector that has been repriced over the past two years.

For landlords, the divergence cuts two ways. Rising capital flows support valuations and deal activity, and well-located, high-quality lab buildings continue to attract both tenants and buyers. But record vacancy means owners of ordinary space face longer lease-up periods, heavier concessions and stiffer competition from a large supply pipeline that was financed in a very different rate environment.

For tenants, the market has tilted in their favor. Biotech and pharmaceutical companies shopping for laboratory space now have more options and more leverage than at any point in the sector's modern history. That bargaining power lets ambitious tenants lock in favorable long-term leases in buildings that would have commanded premium terms during the 2020-2021 boom.

The investment surge suggests buyers believe the vacancy peak reflects a timing mismatch rather than a structural decline. Life sciences real estate is driven by the drug-development pipeline and by research funding, and investors deploying capital now are positioning for a leasing recovery rather than waiting for one to be confirmed.

The record vacancy figure is the number landlords and lenders will watch most closely in coming quarters. If biotech funding recovers and tenants absorb the empty space, the current window of tenant leverage closes and rents firm. If absorption stays slow, the vacancy record could stand for some time, pressuring valuations even as deal volume rises.

The GlobeSt report frames the sector at an inflection point: capital returned before occupancy did. The next phase of the cycle — whether that gap narrows from the demand side or the supply side — will determine whether the current surge in life sciences investment marks a bottom or a bet on a recovery that is still taking shape.